Tamoxifen - What next?

Oncologist

Volumn 9, Issue 4, 2004, Pages 378-384

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Advanced breast cancer; Aromatase inhibitors; Fulvestrant; Sequencing; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DISEASE COURSE; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM CANCER; HUMAN; LETHARGY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOEMBOLISM; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; VAGINA BLEEDING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; HUMANS; TAMOXIFEN;

EID: 3542996262     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-4-378     Document Type: Review

References (51)

1. Ries LG, Eisner MP, Kosary CL et al., eds. SEER Cancer Statistics Review, 1973-1999. Bethesda: National Cancer Institute, 2002. Available at http://seer.cancer.gov/csr/1973-1999/.
2. American Cancer Society. Breast Cancer Facts and Figures. Atlanta: American Cancer Society, 2001. Available at http://www.cancer.org/docroot/STT/ stt_0_2001.asp.
3. Margolese RG, Fisher B, Hortobágyi GN et al. Neoplasms of the breast. In: Bast RC, Kufe DW, Pollock RE et al., eds. Cancer Medicine, Fifth Edition. Hamilton, Canada: BC Decker, 2000:1735-1822.
4. Pritchard KI, Paterson AH, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:2302-2311.
5. Greenberg PA, Hortobágyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
6. Buzdar AU, Hortobágyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-534.
7. Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwestern Oncology Group study. J Clin Oncol 1992;10:1284-1291.
8. Jordan VC, Dowse LJ. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol 1976;68:297-303.
9. 1 phase. Cancer Res 1983;43:3583-3585.
10. Colletti RB, Roberts JD, Devlin JT et al. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882-1884.
11. Cameron DA, Keen JC, Dixon JM et al. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer 2000;36:845-851.
12. Cameron DA, Ritchie AA, Miller WR. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. Eur J Cancer 2001;37:1545-1553.
13. Yao K, Jordan VC. Questions about tamoxifen and the future use of antiestrogens. The Oncologist 1998;3:104-110.
14. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-1152.
15. Kiang DT, Frenning DH, Vosika GJ et al. Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 1980;45:1322-1325.
16. Smith IE, Harris AL, Morgan M et al. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982;42(suppl 8):3430s-3433s.
17. Muss HB, Wells HB, Paschold EH et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis-a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6:1098-1106.
18. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 2002;62:957-966.
19. Jordan VC. Estrogens and antiestrogens. In: Bast RC, Kufe DW, Pollock RE et al., eds. Cancer Medicine, Fifth Edition. Hamilton, Canada: BC Decker, 2000:743-750.
20. Falkson HC, Gray R, Wolberg WH et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 1990;8:599-607.
21. Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881-887.
22. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J Natl Cancer Inst 1998;90:1371-1388.
23. Honig SF, Wysowski DK, Beitz J. Uterine sarcoma and tamoxifen: poor prognosis compared to endometrial adenocarcinoma. Proc Am Soc Clin Oncol 2002;21:41a.
24. Howell A, Howell SJ, Clarke R et al. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol 2001;79:227-237.
25. Bonneterre J, Thürlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-3757.
26. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
27. Harvey H. Clinical use of aromatase inhibitors in breast carcinoma. In: Bast RC, Kufe DW, Pollock RE et al. eds. Cancer Medicine, Fifth Edition. Hamilton, Canada: BC Decker, 2000:751-759.
28. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
29. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
30. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients-a randomized phase III trial of the EORTC group. Proc Am Soc Clin Oncol 2004 (in press).
31. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
32. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1998;27:721-728.
33. Santen RJ, Manni A, Harvey H et al. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-265.
34. Cheung KL, Willsher PC, Pinder SE et al. Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 1997;45:219-224.
35. Aisner J, Tchekmedyian NS, Moody M et al. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. Semin Hematol 1987;24(suppl 1):48-55.
36. Goss PE, Gwyn KM. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994;12:2460-2470.
37. Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-3366.
38. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
39. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-1411.
40. Lønning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-2244.
41. Bertelli G, Garrone O, Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60a.
42. Fawell SE, White R, Hoare S et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883-6887.
43. McClelland RA, Gee JM, Francis AB et al. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 1996;32A:413-416.
44. DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408-414.
45. Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17betadiol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-6746.
46. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
47. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
48. Cheung KL, Robertson JF, Scott N et al. Endocrine response after prior treatment with fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. Eur J Cancer 2002;38(suppl):S98.
49. Vergote I, Robertson JF, Kleeberg U et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207-211.
50. Howell A, Robertson JF. Sensitivity to endocrine therapy is maintained in both fulvestrant- and tamoxifen-treated postmenopausal women with advanced breast cancer. Poster presented at the European Society for Clinical Oncology Congress (ESMO), Nice, France, 18-22 October, 2002.
51. Perey L, Thürlimann B, Hawle H et al. Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors (AIs): an ongoing phase II SAKK trial. Eur J Cancer 2002;38(suppl)::S98.